Announcement • Jul 17
Telo Genomics Provides Positive Interim Data from Ongoing Clinical Trial Advancing Genomic Instability-Based Relapse Risk Assessment Telo Genomics Corp. announced positive interim results from an ongoing retrospective clinical study conducted in collaboration with National and Kapodistrian University of Athens. The clinical trial, which is expected to conclude in summer 2026, analyzes baseline blood samples from multiple myeloma patients treated with standard-of-care regimens. The study cohort includes patients with known two-year clinical outcomes, enabling direct comparisons between patients who relapsed and those who remained in remission. The interim analysis evaluated diagnostic blood samples from 50 multiple myeloma patients with sufficient follow-up data. The study identified “Average Distance to Nuclear Center,” a telomere-associated nuclear architecture parameter linked to genomic instability, as the strongest predictor of relapse status. Receiver Operating Characteristic (ROC) analysis demonstrated strong discriminatory performance, with the assay achieving an Area Under the Curve (AUC) of 0.849, a level considered highly predictive in clinical diagnostics. The interim data suggest that Telo Genomics’ platform may offer a differentiated precision-medicine approach to multiple myeloma by combining disease detection, relapse-risk prediction, and monitoring of disease progression in a single genomic instability-based assay. Specifically, the interim results demonstrate several important clinical and technological capabilities: Telomere-driven nuclear architecture patterns may serve as predictive biomarkers of relapse risk. The platform may identify biologically aggressive disease not apparent through conventional residual disease measurements. The assay may combine residual disease detection and relapse-risk stratification within a single test. Serial 3D telomere profiling may enable monitoring of disease evolution over time. Blood-based testing may reduce dependence on repeated bone marrow sampling. To the Company's knowledge, no clinically implemented MRD scoring model currently integrates residual disease detection with single-cell genomic-instability profiling to predict relapse risk in this manner. Telo Genomics combines highly sensitive CTC detection with single-cell 3D telomere profiling to assess the genomic instability and biologic behavior of residual tumor cells. This approach has the potential to provide relapse-risk stratification that complements tumor-burden measurements and supports clinically important treatment decisions. The Company believes the platform’s ability to combine MRD assessment, malignant cell identification, and relapse-risk prognostication within a single assay could support more personalized treatment decisions and improve clinical management of multiple myeloma patients. Telo Genomics has also partnered with the Cleveland Clinic and Montreal Jewish General Hospital to analyze MRD in a cumulative cohort of approximately 20 multiple myeloma patients, with blood and bone marrow samples from different stages of treatment progression. Telo Genomics previously demonstrated an analytical limit of detection of one tumor cell per 10 million white blood cells, which was published in BioTechniques (PMID: 41873241). Building on these findings, the current study is designed to directly compare Telo Genomics' ability to isolate and characterize circulating tumor cells from peripheral blood in a clinical multiple myeloma cohort against NGS-based MRD results by Adaptive Biotechnologies' ClonoSEQ®, a leading NGS-based MRD platform. In addition to MRD status assessment, the study evaluates Telo Genomics platform by incorporating serial three-dimensional telomere profiling of circulating tumor cells. The studies are designed to longitudinally monitor both MRD status and genomic instability over time, enabling evaluation of how changes in telomere architecture correlate with disease evolution, treatment response and eventual clinical outcomes. Telo Genomics intends to continue validating its technology against current standards of care, including directly with EuroFlow, Adaptive and other established MRD methodologies, with broader validation efforts expected through the end of 2026. MRD refers to the small number of cancer cells that remain in the body after treatment and may ultimately lead to relapse. MRD testing is increasingly being adopted as an important clinical endpoint in oncology and hematologic malignancies, including multiple myeloma. Existing MRD technologies primarily focus on detecting residual tumor cells and often require invasive bone marrow biopsies. Telo Genomics’ blood-based platform is designed to add prognostic insight by analyzing 3D telomere architecture and genomic instability associated with disease evolution and relapse risk. Announcement • Jul 10
Telo Genomics Files Patent Application to Protect New Teloview Biomarker Algorithm for Liquid Biopsy Mrd Applications in Multiple Myeloma Telo Genomics filed a U.S. provisional patent application seeking to protect a new TeloView biomarker algorithm for use with liquid biopsy samples, even those with minimal residual disease in the management of patients with multiple myeloma. The latest patent application aims to protect a new TeloView algorithm that can predict the risk of relapses in multiple myeloma patients and the workflow to isolate circulating cancer cells from peripheral blood samples in the minimal residual disease setting. This expanded IP portfolio will strengthen Telo’s competitive position, support future commercial partnerships, and further differentiate TeloView from existing minimal residual disease technologies. TeloView is a proprietary diagnostic platform which analyzes the three-dimensional telomere and nuclear architecture to assess genomic instability, a fundamental driver of cancer progression. This technology works even at the level of single cell analysis. The platform has generated multiple prognostic algorithms applicable in oncology and neurodegenerative diseases. Telo continues to expand its intellectual property portfolio to protect these clinical applications, with patent coverage for TeloView extending through 2043. Minimal residual disease is an FDA-approved clinical endpoint, and minimal residual disease assessment has become an increasingly important component of multiple myeloma clinical practice, research, and drug development. However, currently available minimal residual disease technologies primarily measure residual tumor burden and generally require invasive bone marrow samples, limiting their suitability for routine longitudinal monitoring of patients and providing limited insight into the biological status of that residual disease. Telo’s peripheral blood minimal residual disease development program aims to validate a non-invasive clinical assay that can regularly measure the presence or absence of minimal residual disease and additionally provide a measure of the risk of relapse to guide the use of therapeutics. Telo expects such an assay to lower healthcare costs and improve patient care outcomes. One of the ongoing studies to validate this clinical test is based on a collaboration with the University of Athens who has provided a large cohort of liquid biopsy samples for minimal residual disease testing where there are commensurate EuroFlow results to compare. Provisional patent applications are not examined by the USPTO and may not result in issued patents. Any future patent protection, if granted, may be narrower than the application as filed. New Risk • Jun 03
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.3m free cash flow). Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-CA$970k). Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$6.53m market cap, or US$4.71m). 
